Internal research and development programs for multiple novel cell therapy candidates and played a pivotal role in establishing and managing external cell-based immuno-oncology collaborations. A novel cell-based product development, including the development of adoptive immunotherapies in the areas of auto-immunity and cancer immunology, Stewart is uniquely positioned to drive the advancement of our preclinical therapeutic pipeline.
Therapeutics has expanded its immunotherapy pipeline, having entered into three strategic collaborations aimed at advancing the development of programmed CD34+ cell, natural killer (NK) cell and T cell immunotherapeutics. To develop off-the-shelf NK cell-based cancer immunotherapeutics including those derived from genetically-engineered induced pluripotent stem cells, a research to accelerate the development of an adoptive PD-L1 programmed CD34+ cellular immunotherapeutic for the treatment of autoimmune diseases such as type 1 diabetes, and a strategic research collaboration with Therapeutics to program the therapeutic profile of genetically-engineered T cell-based cancer immunotherapeutics. In cell programming provides a unique opportunity for developing novel and distinct cellular therapeutics with disease-transforming potential. Its robust immunotherapy pipeline and pioneer the development of next-generation immunotherapeutics based on induced pluripotent stem cell technology.